
Roche

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1 pricing and product initiatives of competitors;
2 legislative and regulatory developments and economic conditions;
3 delay or inability in obtaining regulatory approvals or bringing products to market;
4 fluctuations in currency exchange rates and general financial market conditions;
5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6 increased government pricing pressures;
7 interruptions in production;
8 loss of or inability to obtain adequate protection for intellectual property rights;
9 litigation;
10 loss of key executives or other employees; and
11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com

Roche

Q1 2024 sales

Basel, 24 April 2024

Group

Thomas Schinecker
Chief Executive Officer

Performance

Outlook

Q1 2024: Strong base business growth in both divisions

Good pipeline progress, COVID-19 and currency headwinds diminishing

Group sales +2% at CER driven by strong base business of +7%

- Strong Pharma (+7% at CER) and Diagnostics (+8% at CER) base business growth
- COVID-19 sales decreased by CHF -0.7bn and LOE[1] impact was CHF -0.4bn, both in line with guidance

Key milestones achieved in Q1

- Pharma regulatory: US approval for Xolair in food allergy and Alecensa in adjuvant ALK+ NSCLC, US filing for inavolisib in 1L *PIK3CA*-mut HR+ BC
- Pharma readouts: Positive Ph III (STARGLO) Columvi in 2L+ DLBCL, positive Ph II (KARDIA-2) zilebesiran in hypertension
- Diagnostics regulatory: US approval for molecular blood screening for malaria, FDA BDD for pTau217 AD rule-in blood test

Significant newsflow in 2024

- Pivotal readouts: Ph III (SUNMO) Lunsumio in 2L+ DLBCL, Ph III (SKYSCRAPER-01) tiragolumab in 1L NSCLC, Ph III (VERONA) Venclexta in 1L MDS and Ph III (REGENCY) Gazyva in LN
- Ph III enabling readouts: Ph I/II (Brainshuttle AD) trontinemab in AD, Ph IIb (PADOVA) prasinezumab in PD, Ph II (MANATEE) Evrysdi + GYM329 in SMA, Ph II (GOLDEN STUDY) ASO factor B in GA, Ph II (BARDENAS/ALLUVIUM) vamikibart in DME and Ph I/II data for CT-388/CT-868/CT-996 in obesity
- Filing: Ph III (EMBARK) Elevidys in DMD in EU
- Diagnostics launches: i601 mass spectrometry, Accu-Chek SmartGuide (CGM), cobas c703 and ISE neo, cobas 6800 / 8800 v2.0, cobas pro serology solution, cobas Liat Respiratory Panel and cobas Respiratory flex

Base business=Pharma excluding Ronapreve and Diagnostics excluding COVID-19-related products; [1]loss of exclusivity impact includes global losses on Avastin, Herceptin, Mabthera/Rituxan, Esbriet, Lucentis and Actemra; Growth numbers and rates at CER (Constant Exchange Rates); HR+=hormone receptor positive; *PIK3CA*-mut=phosphoinositide 3-kinase mutant; BC=breast cancer; NSCLC=non-small cell lung cancer; DLBCL=diffuse large B-cell lymphoma; MDS=myelodysplastic syndromes; LN=lupus nephritis; DMD=Duchenne muscular dystrophy; PD=Parkinson's disease; BDD=Breakthrough Device Designation; AD=Alzheimer's disease; SMA=spinal muscular atrophy; ASO=antisense oligonucleotide; GA=geographic atrophy; DME=diabetic macular edema; CGM=continuous glucose monitoring; ISE=ion selective electrode

Q1 2024: Base business growing at +7%

Both divisions with continued strong momentum

	2024 CHFbn	2023 CHFbn	Change in % CHF	Change in % CER	Excl. C19[1]
Pharmaceuticals Division	**10.9**	11.6	**-6**	**2**	**7**
Diagnostics Division	**3.5**	3.7	**-6**	**2**	**8**
Roche Group	**14.4**	15.3	**-6**	**2**	**7**

[1]Base business=Pharma excluding Ronapreve and Diagnostics excluding COVID-19-related products; CER=Constant Exchange Rates; totals may include differences due to rounding

Q1 2024: Base business overcompensating for COVID-19 and LOE

Currency impact of -8%p in Q1, current full year projection of -2%p



Base business=Pharma excluding Ronapreve and Diagnostics excluding COVID-19-related products; CER=Constant Exchange Rates; LOE=loss of exclusivity impact includes global losses on Avastin, Herceptin, Mabthera/Rituxan, Esbriet, Lucentis and Actemra

Q1 2024: Strong momentum in the base business for the Group

No material COVID-19 impact going forward

Roche Group

Annual sales evolution 2018-2024



Base business=Pharma excluding Ronapreve and Diagnostics excluding COVID-19-related products; Growth rates at CER (Constant Exchange Rates) of the respective year

Q1 2024: Base businesses in both divisions grow high single digit

No material COVID-19 impact going forward

Pharma*

Quarterly sales evolution 2022-2024



Diagnostics*

Quarterly sales evolution 2022-2024



Base business=Pharma excluding Ronapreve and Diagnostics excluding COVID-19-related products; Growth rates at CER (Constant Exchange Rates) of the respective year;
*FMI sales for divisional growth rates included in Pharma for 2022 vs 2021 and in Diagnostics for 2023 vs 2022 and 2024 vs 2023 comparisons

Pipeline update: Strengthening the Pharma pipeline

Portfolio shaping ongoing: Focus on high-impact projects led to termination of 20% of total NMEs since Q3 23

NME changes in Q1

		Phase	Indication
+	LepB inhibitor (RG6436)	I	UTI
–	camonsertib	I	Solid tumors
–	belvarafenib	I	Solid tumors
–	RG6286	I	CRC
–	LepB inhibitor (RG6319)	I	UTI
–	RG6163	I	Psychiatric disorders

NME and LE (QoQ change, Q1 24 vs Q4 23)



NME=new molecular entity; LE=line extension; CRC=colorectal cancer; UTI=urinary tract infection; includes all assets from Ph I to Registration

Vacaville sale: Optimizing our Pharma manufacturing network



- Vacaville site sold for USD ~1.2bn*
- Global network investment to enable portfolio evolution
- Building capabilities in new modalities: Cell & gene therapy, oligonucleotides and peptides
- Network optimization including balancing for geographical needs ongoing

11 manufacturing sites with a total of >530,000L biologics capacity serving global demand**

*Contingent on deal closing; **Total capacity excluding Vacaville and including Chugai; China and Japan operations are partnered locations; Volumes referring to drug substance volumes

Optimizing manufacturing network to address portfolio evolution

Addressing the demands of producing diverse molecules with smaller volume production needs



- Overall 5x productivity improvement* through higher cell line yields, improved media and perfusion technology
- Portfolio shift to smaller volumes due to more high-potency NMEs
- Lower drug substance demand due to manufacturing improvements and portfolio evolution

NME=new molecular entity; Small volume=less than 10 runs at 12kL scale; *Expected from 2000-2030; Volumes referring to drug substance volumes

Realizing synergies in Diagnostics and the Group

Acting on opportunities across the Group to improve operational performance

FMI

Shift of FMI from Pharma to Diagnostics Division

Combine our Diagnostics and FMI expertise

Utilize broad Diagnostics portfolio to the benefit of FMI

Leverage our next generation sequencing capabilities

Near Patient Care*

Integration of Point of Care and Diabetes Care

Leverage complementary patient/customer segments and technologies

Operate impactfully as one division

Re-invest savings in strategic growth areas

*Integration of the customer areas Point of Care and Diabetes Care results in the new customer area Near Patient Care

Performance

Outlook

Young portfolio to drive growth in the near- to mid-term

Two NME approvals expected for 2024: PiaSky (crovalimab) in PNH[1] and inavolisib in HR+ breast cancer



Potential NME launches:
- **crovalimab**
- **inavolisib**



Young portfolio defined as all launches since end of 2015; [1]PiaSky (crovalimab) in PNH approved in Japan and China with US/EU approvals expected in 2024; [2]Elevidys: Accelerated US approval by partner company Sarepta; [3]Venclexta sales booked by AbbVie and therefore not included; NME=new molecular entity; PNH=Paroxysmal Nocturnal Hemoglobinuria; HR=hormone receptor

Declining COVID-19 related headwinds in 2024

Q1 2024 is the final quarter materially impacted by declining COVID-19 sales, minor impact expected in Q4



Roche with total COVID-19 sales of ~ CHF 19bn*

*COVID-19 sales referring to COVID-19 diagnostic tests, Ronapreve and Actemra sales; all values at CER A23 (Constant Exchange Rate Average 2023)

Key growth drivers beyond 2025

Many opportunities with significant market potential in both divisions

Pharmaceuticals

	NME	Indication	Newsflow	Timing
Oncology / Hematology	**tiragolumab**	NSCLC	Final Ph III data	H2 2024
	inavolisib	BC	US/EU filing	2024
	divarasib	NSCLC	Ph I/II readout	2024/25
	giredestrant	BC	Ph III readout	2025
Neurology	**Elevidys**	DMD	Ph III readout	2024/25
	prasinezumab	PD	Ph IIb readout	2024
	Evrysdi + GYM329	SMA	Ph II readout	2024
	trontinemab	AD	Ph I/II readout	2024
	fenebrutinib	MS	Ph III readout	2025
Immunology	**Gazyva**	LN	Ph III readout	2024
	anti-TL1A	IBD	Ph III initiation	2024
	astegolimab	COPD	Ph III readout	2025
Ophthalmology	**vamikibart (anti-IL6)**	DME/UME	Ph II/III readout	2024/25
	ASO factor B	GA	Ph II readout	2024
Cardiovascular & Metabolism	**zilebesiran**	HT	Ph II readout	2024
	CT-388/868/996 (GLP-1/GIP)	Obesity	Ph I/II readout	2024

Diagnostics

	Product	Description	Launch
Core Lab	**i601 mass spec**	Total solution for clinical mass spectrometry and first reagent ipack	2024
	cobas pro serology solution	Roche blood safety solution for the US donor screening market	2024
	cobas c703 & ISE neo	High-throughput clinical chemistry and ISE testing on cobas pro	2024
	Elecsys Amyloid Plasma Panel	Rule-out blood-based test for amyloid pathology detection in AD	2025
Molecular Lab	**cobas 6800/8800 v2.0**	Upgrade with increased testing flexibility, throughput and automation	2024
	cobas Respiratory flex	Novel TAGS® multiplex technology for respiratory testing on cobas x800	2024
	Next generation sequencing	Nanopore sequencer with unique sequencing by expansion technology	2025+
Near Patient Care	**Accu-Chek SmartGuide**	Roche's first generation continuous glucose monitoring solution	2024
	cobas Liat Resp. panel	Detection & differentiation of four most prevalent respiratory targets	2024

Key growth drivers beyond 2025

Many opportunities with significant market potential in both divisions

Pharmaceuticals

	NME	Indication	Newsflow	Timing
Oncology / Hematology	tiragolumab	NSCLC	Final Ph III data	H2 2024
	inavolisib	BC	US/EU filing	2024
	divarasib	NSCLC	Ph I/II readout	2024/25
	giredestrant	BC	Ph III readout	2025
Neurology	Elevidys	DMD	Ph III readout	2024/25
	prasinezumab	PD	Ph IIb readout	2024
	Evrysdi + GYM329	SMA	Ph II readout	2024
	trontinemab	AD	Ph I/II readout	2024
	fenebrutinib	MS	Ph III readout	2025
Immunology	Gazyva	LN	Ph III readout	2024
	anti-TL1A	IBD	Ph III initiation	2024
	astegolimab	COPD	Ph III readout	2025
Ophthalmology	vamikibart (anti-IL6)	DME/UME	Ph II/III readout	2024/25
	ASO factor B	GA	Ph II readout	2024
Cardiovascular & Metabolism	**zilebesiran**	HT	Ph II readout	2024
	CT-388/868/996 (GLP-1/GIP)	Obesity	Ph I/II readout	2024

Diagnostics

	Product	Description	Launch
Core Lab	i601 mass spec	Total solution for clinical mass spectrometry and first reagent ipack	2024
	cobas pro serology solution	Roche blood safety solution for the US donor screening market	2024
	cobas c703 & ISE neo	High-throughput clinical chemistry and ISE testing on cobas pro	2024
	Elecsys Amyloid Plasma Panel	Rule-out blood-based test for amyloid pathology detection in AD	2025
Molecular Lab	cobas 6800/8800 v2.0	Upgrade with increased testing flexibility, throughput and automation	2024
	cobas Respiratory flex	Novel TAGS® multiplex technology for respiratory testing on cobas x800	2024
	Next generation sequencing	Nanopore sequencer with unique sequencing by expansion technology	2025+
Near Patient Care	**Accu-Chek SmartGuide**	Roche's first generation continuous glucose monitoring solution	2024
	cobas Liat Resp. panel	Detection & differentiation of four most prevalent respiratory targets	2024

Positive 2024 outlook

Sales drivers[1]

Continued strong base business growth in both divisions

COVID-19 sales expected to decline by roughly CHF 1.1bn

LOE[2] impact of roughly CHF 1.6bn expected

Group sales growth[1]	Mid single digit sales growth

Base business=Pharma excluding Ronapreve and Diagnostics excluding COVID-19-related products; [1]At Constant Exchange Rates (CER); [2]LOE impact includes global losses on Avastin, Herceptin, Mabthera/Rituxan, Esbriet, Lucentis and Actemra

2024 guidance confirmed

Group sales growth[1]	Mid single digit sales growth
Core EPS growth[1]	Broadly in line with sales growth excl. impact from resolution of tax disputes in 2023
Dividend outlook	Further increase dividend in Swiss francs

[1]At Constant Exchange Rates (CER)

Finance

Alan Hippe
Chief Financial Officer

Q1 2024: Regional Pharma and Diagnostics sales bridge

CER Group sales increase of +2%



Absolute values in CHFm at Constant Exchange Rates (avg full year 2023); ¹avg. full year 2023 to avg Q1 2024 Fx impact

Pharma: Optimizing our manufacturing network

Working on and protecting profitability

Successful diversification and rejuvenation of Pharma portfolio



Broadly stable manufacturing costs despite strong volume growth and diversification



[1]Pharma including FMI; CER=Constant Exchange Rates (avg. full year 2022 as basis calculating back with the CER growth rate of the respective year);
AHR=Avastin, Herceptin and Rituxan/MabThera; COGS + PC=manufacturing cost of goods sold and period costs

Exchange rate impact on sales growth

Negative impact driven by the USD, JPY, CNY (APAC) and EUR



CER=Constant Exchange Rates (avg full year 2023)

Expected 2024 currency impact



Assuming the 29 March 2024 exchange rates remain stable until end of 2024,
2024 impact[1] is expected to be (%p):

	Q1	Q2	Q3	Q4
Sales	**-8**	**-2**	**+1**	**+1**

	Q1	HY	Sep YTD	FY
Sales	**-8**	**-5**	**-3**	**-2**
Core operating profit		**-7**		**-4**
Core EPS		**-8**		**-5**

[1]On group growth rates

2024 outlook confirmed

Group sales growth[1]	Mid single digit sales growth
Core EPS growth[1]	Broadly in line with sales growth excl. impact from resolution of tax disputes in 2023
Dividend outlook	Further increase dividend in Swiss francs

[1]At Constant Exchange Rates (CER)

Diagnostics: New customer area structure 2024

Changes effective 1 Jan, 2024, comparative information for 2023 has been restated accordingly



1 Sales in the Molecular Lab customer area include sales from the Foundation Medicine business which moved under the responsibility of the Diagnostics Division from the Pharma Division effective 1 Jan, 2024.

2 Sales in the new Near Patient Care customer area include sales from Diabetes Care and the Point of Care business, both previously shown as separate customer areas.

- The comparative information for 2023 has been restated accordingly.

Restatements to be applied in 2024

Foundation Medicine shifted to the Diagnostics Division effective 1 Jan, 2024

Income statement (Core)

Pharmaceuticals Division - CHFm	Half Year 2023 Published	Half Year 2023 Delta	Half Year 2023 Restated	Full Year 2023 Published	Full Year 2023 Delta	Full Year 2023 Restated
Sales	22,681	-170	22,511	44,612	-347	44,265
Other revenue	806	-8	798	1,667	-19	1,648
Cost of sales	-4,107	71	-4,036	-8,343	149	-8,194
Research and development	-5,617	110	-5,507	-11,490	204	-11,286
Selling, general and administration	-3,444	136	-3,308	-7,215	263	-6,952
Other operating income (expense)	699	0	699	758	1	759
Core operating profit	**11,018**	**139**	**11,157**	**19,989**	**251**	**20,240**
Core operating profit margin	*48.6%*	*1.0%p*	*49.6%*	*44.8%*	*0.9%p*	*45.7%*

Diagnostics Division - CHFm	Half Year 2023 Published	Half Year 2023 Delta	Half Year 2023 Restated	Full Year 2023 Published	Full Year 2023 Delta	Full Year 2023 Restated
Sales	7,098	170	7,268	14,104	347	14,451
Other revenue	31	8	39	58	19	77
Cost of sales	-3,349	-71	-3,420	-6,908	-149	-7,057
Research and development	-832	-110	-942	-1,747	-204	-1,951
Selling, general and administration	-1,342	-136	-1,478	-2,899	-263	-3,162
Other operating income (expense)	13	0	13	60	-1	59
Core operating profit	**1,619**	**-139**	**1,480**	**2,668**	**-251**	**2,417**
Core operating profit margin	*22.8%*	*-2.4%p*	*20.4%*	*18.9%*	*-2.2%p*	*16.7%*

Upcoming Roche IR events 2024

Additional events driven by readouts

Diagnostics Day May 22

- Deep-dive into the current product portfolio
- Updates on key development projects and upcoming launches, including mass spectrometry, CGM, NGS

Oncology/ASCO May 31

- Oncology solid tumors pipeline update (tiragolumab, giredestrant, inavolisib, divarasib)
- Malignant hematology portfolio and pipeline update
- Data presented at ASCO

Ophthalmology/ASRS Jul 23

- Ophthalmology franchise update
- Ophthalmology pipeline (early- and late-stage)
- Data presented at ASRS

Pharma Day Sep 30

- Update on Group & Pharma strategy
- Update on R&D excellence
- Deep-dive into the current product portfolio
- Building blocks for future growth: Late stage pipeline update

Neurology Update ✓	**Diagnostic Day**	**Oncology/ASCO**	**Ophthalmology/ASRS**	**Pharma Day**
Virtual	London & virtual	Virtual	Virtual	London & virtual
Mon, 11 Mar	Wed, 22 May	Fri, 31 May	Tue, 23 Jul	Mon, 30 Sep
15:00-16:30 CET	13:00-15:30 BST	16:00-17:30 CEST	16:30-17:30 CEST	tbd

CGM=continuous glucose monitoring; NGS=next generation sequencing; ASCO=American Society of Clinical Oncology; ASRS=American Society of Retina Specialists

Pharmaceuticals Division

Teresa Graham
CEO Roche Pharmaceuticals

Q1 2024: Pharmaceuticals sales

All regions ex-Japan delivering strong growth, Japan impacted by Ronapreve sales in Q1 2023

	2024 CHFm	2023 CHFm	Change in % CHF	Change in % CER	CER w/o Ronapreve
Pharmaceuticals Division	**10,921**	**11,608**	**-6**	**2**	**7**
United States	5,692	5,763	-1	5	5
Europe	2,200	2,071	6	11	11
Japan	649	1,390	-53	-45	-6
International	2,380	2,384	0	12	12

CER=Constant Exchange Rates

Q1 2024: Young portfolio delivering strong growth

Phesgo now second strongest growth driver; Vabysmo excellent growth momentum continues



Absolute values and growth rates at Constant Exchange Rates (CER)

US filing for inavolisib in 1L *PIK3CA-mut* HR+ BC completed

Strong Phesgo launch continues, conversion rate climbing to 41%*

IR event at ASCO on May 31st



CHFm / YoY CER growth

Q1 update

- Perjeta: Ongoing conversion to Phesgo, partially offset by growth in International
- Phesgo: Strong launch uptake and ongoing geographic expansion
- Tecentriq: Growth driven by adjuvant NSCLC and 1L HCC in ex-US; EU launch of SC formulation ongoing
- Kadcyla: Growth in International compensating for US/EU
- Alecensa: Global market leader in 1L ALK+ mNSCLC
  - US approval in adj. ALK+ NSCLC (ALINA) achieved

Outlook 2024

- Tecentriq SC for various indications: US approval (PDUFA 15th Sep)
- Alecensa in adj. ALK+ NSCLC (ALINA): EU approval
- Inavolisib in 1L *PIK3CA-mut* HR+ BC (INAVO120): EU filing
- Ph III (SKYSCRAPER-01) tiragolumab + Tecentriq in 1L PD-L1+ NSCLC final OS results expected in H2 2024

*Perjeta/Phesgo conversion rate calculated using volumes, currently taking 46 launch countries into account; CER=Constant Exchange Rates; PIK3CA-mut=phosphatidylinositol 3-kinase, catalytic, alpha polypeptide mutated; HR=hormone-receptor; BC=breast cancer; NSCLC=non-small cell lung cancer; HCC=hepatocellular carcinoma; SC=subcutaneous; PDUFA=prescription drug user fee act; ALK=anaplastic lymphoma kinase; PD-L1=programmed death-ligand 1; OS=overall survival

Polivy US patient share in 1L DLBCL (IPI 0-5) climbing to 23%

Positive Ph III (STARGLO) of Columvi in 2L+ DLBCL met primary endpoint of overall survival



Q1 update

- Hemlibra: Continued penetration across all approved patient segments with >25,000 patients treated globally
- Polivy: Strong 1L DLBCL uptake in all major markets
- Gazyva: Growth driven by combinations in 1L CLL
- Columvi: Driven by strong 3L+ DLBCL launch; Ph III (STARGLO) in 2L+ DLBCL met primary endpoint of overall survival
- Lunsumio: Driven by strong 3L+ FL launch
- PiaSky (crovalimab) in PNH: First approvals in Japan and China

Outlook 2024

- PiaSky (crovalimab) in PNH (COMMODORE 2/1): US/EU approval
- Ph III (SUNMO) Lunsumio + Polivy in 2L+ DLBCL
- Ph III (VERONA) Venclexta + azacitidine in 1L MDS

*Venclexta sales booked by AbbVie and therefore not included; CER=Constant Exchange Rates; DLBCL=diffuse large B cell lymphoma; CLL=chronic lymphocytic leukemia; FL=follicular lymphoma; PNH=paroxysmal nocturnal hemoglobinuria; MDS=myelodysplastic syndromes; IPI=international prognostic index

Hemlibra: New convenience options planned for 2024/2025

Global SoC in Hemophilia A with extensive real-world data

Update on administration options at ISTH (June 22-26)

Hemlibra's extensive clinical and real-world evidence base

Efficacy in RWD	Sustained bleed protection with low ABR (mean/median)*	~80% of patients with zero treated bleeds**
Safety	Favorable safety profile established through >10 yrs of clinical studies & follow up	Does not induce FVIII inhibitor development
Convenience	>60% of pts on Q2W/Q4W SC dosing; paediatric self-admin from 7yrs old	2 new vial options available & new admin kit coming

Hemlibra's strong efficacy / safety profile across clinical trials confirmed by RWD:

>25,000 patients treated	>10 yrs of study	>100 RWD publications

*RWD across >100 publications: Mean ABR range 0.2-1.4 while Median ABR range 0.0-1.0 for treated bleed; **Based on RWD from McCary I, et al. Haemophilia 2020, Wall C, et al. ISTH 2020, Poon M-C, et al. ASH 2022 and Khairnar R, et al. ASH 2021; ABR=annual bleed rate; RWD=real-world data; Q2W=every 2 weeks; SC=subcutaneous; SoC=standard of care

EU filing of Elevidys in DMD planned for 2024

Ocrevus market leader in US/EU5 with 24% global patient share



CHFm / YoY CER growth

Q1 update

- Ocrevus: Remaining #1 in new to brand in US; higher retention rate than other MS medicines
- Evrysdi: Global market leader in patients share and total patients, with >15k patients treated globally
- Elevidys Ph III (EMBARK) data shared at MDA 2024 and with EMA
  - First ex-US patient treated in UAE
- Trontinemab: Data for the 3.6mg dose presented at AD/PD, confirming safety profile and rapid amyloid plaque clearance

Outlook 2024

- Ocrevus 6m SC (OCARINA II): US (PDUFA 13th Sep)/EU approval
- Elevidys in DMD (EMBARK): EU filing
- Ph II (MANATEE) Evrysdi + GYM329 in SMA interim
- Ph IIb (PADOVA) prasinezumab in PD
- Ph Ib/IIa (Brainshuttle™ AD) trontinemab in AD updated data

CER=Constant Exchange Rates; DMD=Duchenne muscular dystrophy; MS=multiple sclerosis; SC=subcutaneous; SMA=spinal muscular atrophy; PD=Parkinson's disease; AD=Alzheimer's disease; PDUFA=prescription drug user fee act; UAE=United Arab Emirates

Achieved US approval for Xolair in food allergy

Gazyva Ph III (REGENCY) in lupus nephritis to readout in 2024



CHFm / YoY CER growth

Q1 update

- Xolair: Growth driven by strong CSU performance; market shares in Asthma declining; food allergy launch commencing
  - Positive Ph III (OUtMATCH) results in food allergy presented at AAAAI 2024 and published in NEJM[1]
- Actemra: Stable sales despite first biosimilars launched
- Astegolimab in COPD: Recruitment for pivotal program nearing completion

Outlook 2024

- Ph III (REGENCY) Gazyva in lupus nephritis
- Ph III trials of anti-TL1A in IBD to be initiated

[1]Wood et al., 2024 NEJM; CER=Constant Exchange Rates; RA=Rheumatoid arthritis; IBD=inflammatory bowel disease; TL1A=Tumor necrosis factor-like cytokine 1A; CSU=chronic spontaneous urticarial; COPD=chronic obstructive pulmonary disease

Xolair: First medicine to reduce allergic reactions to multiple foods

Potential to redefine the way food allergies are managed

Ph III (OUtMATCH) in food allergy[1,*]



- Xolair is the first and only FDA approved medicine to reduce allergic reactions for children and adults with one or more food allergies
- >40% of children and >50% of adults with food allergies have experienced a severe reaction at least once[2,3]

[1]Wood et al., 2024 NEJM; [2]Gupta et al., 2019 JAMA Netw Open; [3]Gupta et al., 2018 Pediatrics; *The phase III OUtMATCH study is being sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, and conducted by the NIAID-funded Consortium of Food Allergy Research (CoFAR) across 10 clinical sites throughout the U.S. The study is also supported by Genentech, a member of the Roche Group, and Novartis Pharmaceuticals Corporation; CI=confidence interval

Vabysmo US market share further expanding in nAMD and DME

Strong momentum for US launch of Vabysmo in RVO reaching 8% market share after only 4 months*



CHFm / YoY CER growth

IR event at ASRS on July 23rd

Q1 update

- Vabysmo: Continued market share gains across early launch countries and ongoing global expansion
  - US: Increasing penetration in naïve patients
  - Network meta-analysis shows improved anatomic outcomes at 12 weeks for Vabysmo vs. aflibercept 8mg in nAMD and DME
  - Rapidly growing body of RWD confirming drying effect and durability seen in the pivotal studies

Outlook 2024

- Vabysmo in RVO (BALATON/COMINO): EU approval
- Susvimo in nAMD (ARCHWAY): US commercial relaunch
- Susvimo in DME/DR (PAGODA/PAVILION): US filing
- Ph II (BARDENAS/ALLUVIUM) vamikibart in DME
- Ph II (GOLDEN STUDY) ASO factor B in GA

*based on February 2024 Verana patient claims data; CER=Constant Exchange Rates; nAMD=neovascular age-related macular degeneration; DME=diabetic macular edema; RVO=retinal vein occlusion; DR=diabetic retinopathy; RWD=real-world data; GA=geographic atrophy; ASO=antisense oligonucleotide; ASO factor B in collaboration with Ionis

Vabysmo improved anatomic results vs. aflibercept 8mg in NMA

Greater CST improvements vs aflibercept 2mg and 8mg after the monthly loading phase (week 12)

Comparative efficacy of Vabysmo: A Systematic Literature Review and Network Meta-Analysis[1]

The Macula Society Established in 1977

Methodology*



Mean difference in CST change from baseline for Vabysmo vs aflibercept 2mg/8mg at 12 weeks (µm, RE model, 95% CrI)**



- Systematic literature reviews and NMA are validated tools for making comparisons across clinical trials
- NMA shows that Vabysmo in nAMD & DME achieves greater CST reduction compared to aflibercept 8mg during the loading phase at week 12
- Analysis insights add to growing body of evidence supporting Vabysmo as the preferred choice for 1L treatment in both nAMD and DME

[1]Leng, T et al., Macula Society 2024; *Trials included in the analysis and their respective patient counts: nAMD=TENAYA/LUCERNE (n=671/658), PULSAR (n=1009), CANDELA (n=106); DME= YOSEMITE/RHINE (n=940/951), PHOTON (n=659); Bayesian NMA outcomes of interest= BCVA & CST change through week 12 and differences & probability of better outcomes with Vabysmo; **For all treatments data of intravitreal Q4W dosing schemes was used for the NMA; SLR=systematic literature review; NMA=network meta-analysis; BCVA=best-corrected visual acuity; CST=central subfield thickness; DME=diabetic macular edema; nAMD=neovascular age-related macular degeneration; RE=random effects; CrI=credible interval; Q4W=every 4 weeks

Vabysmo: Real-world insights substantiate treatment benefits

Rapidly growing body of RWD confirming drying effect and durability seen in the pivotal studies

Vabysmo's growing real-world evidence base

Real-world data

>10
Vabysmo RWD studies published

>50k
Patients analysed in RWD studies

Selected RWD studies

FARETINA	FARWIDE	VOYAGER
nAMD / DME	nAMD / DME	nAMD / DME
n=32,124 / 8,970	n=6,978 / 1,309	n=220 / 107

TRUCKEE	Lueng EH et al.	Pandit SA et al.
nAMD	nAMD	nAMD
n=337	n=190	n=218

Vabysmo at ARVO (May 5-9)

ARVO 2024 May 5 – 9 | Seattle | Vision for the Future

36 RWD focused abstracts

35 Independent abstracts accepted

16 Roche abstracts accepted

"Real-world data supports the data from the pivotal studies regarding the efficacy and safety profile of faricimab in heterogeneous real world patient populations" (Penha F et al., Int J Retina Vitreous. 2024 Jan 17;10(1):5)

RWD=real-world data; nAMD=neovascular age-related macular degeneration; DME=diabetic macular edema

Positive Ph II (KARDIA-2) for zilebesiran as add-on to SoC

Single SC dose showed clinically significant reduction in 24h mean ambulatory and office SBP at 3 months

Ph II (KARDIA-2) results in hypertension[1]



- Zilebesiran demonstrated clinically significant additive reductions in time-adjusted and placebo-adjusted office SBP at 6 months across all three study cohorts, including the maximum dose of olmesartan
- Results support the potential for twice-yearly dosing, and showed an encouraging safety and tolerability profile
- Ph II (KARDIA-3) with zilebesiran as add-on to 2-4 SoC for uncontrolled hypertension with high CV risk initiated

[1] Bakris et al., ACC 2024; *Ambulatory/office blood pressure assessed while patients were receiving or within 2 weeks of stopping any rescue medication is censored; SoC=standard of care; SBP=systolic blood pressure; CI=confidence interval; LSM=least-squares mean; LSMD=LSM difference; CV=cardiovascular; zilebesiran in partnership with Alnylam Pharmaceuticals

2024: Key newsflow*

	Compound	Indication	Milestone	
Regulatory	**Alecensa**	Adjuvant ALK+ NSCLC	US/EU approval	✓ US
	inavolisib + palbociclib + fulvestrant	1L *PIK3CA*-mut HR+ BC	US/EU filing	✓ US
	Tecentriq	Subcutaneous administration	US/EU approval	✓ EU
	crovalimab	PNH	US/EU approval	
	Elevidys	DMD	EU filing	
	Ocrevus 6m SC	RMS/PPMS	US/EU approval	
	Susvimo	DME/DR	US filing	
	Vabysmo	RVO	EU approval	
	Xolair	Food allergy	US approval	✓
Clinical results	**tiragolumab + Tecentriq**	1L PDL1+ NSCLC	Ph III SKYSCRAPER-01	
	Venclexta + azacitidine	1L high risk MDS	Ph III VERONA	
	Columvi + GemOx	2L+ DLBCL	Ph III STARGLO	✓
	Lunsumio + Polivy	2L+ DLBCL	Ph III SUNMO	
	Gazyva	Lupus nephritis	Ph III REGENCY	
	Enspryng	generalized Myasthenia gravis	Ph III LUMINESCE	(✓) *Not to be filed*
	Evrysdi + GYM329	SMA	Ph II MANATEE	
	prasinezumab	Parkinson's disease	Ph IIb PADOVA	
	trontinemab	Alzheimer's disease	Ph Ib/IIa Brainshuttle™ AD	
	vamikibart	DME	Ph II BARDENAS/ALLUVIUM	
	ASO factor B	Geographic atrophy	Ph II GOLDEN STUDY	
	zilebesiran	Hypertension	Ph II KARDIA-2	✓
	CT-388	Obesity w/wo T2D (QW SC)	Ph I	
	CT-868	T1D w. Obesity (QD SC)	Ph II	
	CT-996	Obesity w/wo T2D (QW oral)	Ph I	

*Outcome studies are event-driven: timelines may change

Diagnostics Division

Matt Sause
CEO Roche Diagnostics

Q1 2024: Diagnostics Division sales

Strong base business growth more than offsetting decline in COVID-19 sales

	2024 CHFm	2023 CHFm	Change in % CHF	Change in % CER	Excl. C19[1]
Diagnostics Division	**3,478**	**3,714**	**-6**	**2**	**8**
Core Lab	1,925	1,928	0	9	
Molecular Lab[2]	620	683	-9	-3	
Near Patient Care[3]	570	774	-26	-20	
Pathology Lab	363	329	10	19	

CER=Constant Exchange Rates; [1]Diagnostics Division base business excluding COVID-19-related products; [2]includes FMI; [3]includes Point of Care and Diabetes Care

Q1 2024: Diagnostics highlights

Strong base business growth more than offsetting decline in COVID-19 sales



Base business=excluding COVID-19-related products; CER=Constant Exchange Rates; PoC=Point of Care; EMEA=Europe, Middle East and Africa; [1]includes FMI; [2]includes Point of Care and Diabetes Care

Q1 2024: Diagnostics regional sales

Strong base business growth across all regions



Base business=excluding COVID-19-related products; Growth rates at CER (Constant Exchange Rates); EMEA=Europe, Middle East and Africa

Largest installed base with significant growth potential



+2% Lab SW Solutions

+3% SWA analytical units [1]

of which: cobas® pro / pure +77%

+14% Preanalytics / Connectivity

+20% cobas® 5800/6800/8800

+6% cobas® Liat

+12% HE600

+10% BenchMark ULTRA/ ULTRAPLUS

+29% DP200/DP600

2023 Growth

Growth rates – from 31.12.2022 to 31.12.2023
(Total installed modules as of 31.12.2023)

SWA=Serum Work Area

Accu-Chek SmartGuide CGM solution

Enabling better decision-making for people with diabetes

Accu-Chek SmartGuide CGM solution



Improving diabetes management and care continuum

- Data released at ATTD shows strong performance of first Roche CGM
- 14 days of reliable and accurate real-time glucose sensor data
- Predictive algorithms for 2 hours and night-time hypo
- Addressing the needs of T1D and T2D people on insulin therapy
- Easy HCP data sharing and trusted Accu-Chek quality and customer service

The first predictive CGM solution that proactively helps to act before a problem[1] even occurs

Accu-Chek SmartGuide sensor is pre CE mark. Not available for sale; [1]glucose excursion, i.e. hypo or hyper glycemic event; CGM=continuous glucose monitoring; ATTD=Advanced Technologies & Treatments for Diabetes conference; T1D=type 1 diabetes; T2D=type 2 diabetes; HCP=health care professional

FDA approval for cobas® malaria test

First molecular donor screening test to protect the blood supply from malaria infection

Test provides a more sensitive and specific malaria screening of blood donors versus current methods

Unmet medical need and medical value

- Transfusion-transmitted malaria infection can cause serious complications and death in recipients
- Increases blood safety in endemic countries and reduce donor deferrals in non-endemic countries
- Qualitative NAT detects 5 major species of malaria causing parasites

Workflow benefits

- Proprietary tube allows for direct draw and usage, increasing workflow efficiency in the lab

Projected timeline

- Currently under regulatory review for CE-IVDR approval

NAT=Nucleic Acid Test

FDA BDD granted for pTau217 blood test[1]

Alzheimer's blood tests will substantially improve disease diagnosis

FDA BDD

Elecsys CSF ratios

- tTau, pTau181 & Abeta42
- Sensitivity 90%±3%
- Specificity 90%±3%

FDA BDD

Elecsys Amyloid Plasma Panel

- Biomarkers pTau181 & ApoE4p
- Minimize false negatives (NPV>90%)
- US & EU filing expected 2025

FDA BDD

Rule-in blood test[2]

- Biomarker pTau217
- Minimize false positives (PPV>90%)
- US & EU filing expected 2026



[1]Elecsys® pTau217 plasma biomarker test is being developed as part of an ongoing partnership between Roche and Eli Lilly; [2]Not to replace confirmatory test completely; BDD=breakthrough device designation; CSF= cerebrospinal fluid; NPV=negative predictive value; PPV=positive predictive value

Diagnostics key launches 2024

	Area	Product	Description	Markets	Status
Instruments Automation	Core Lab	i601 mass spectrometry system	Launch of an unique total solution for clinical mass spectrometry testing: fully automated, integrated and IVD-compliant	CE	
		cobas c703	Introducing high-throughput clinical chemistry testing to cobas pro integrated solutions	CE	
		cobas ISE neo	Introducing high-throughput ISE testing to cobas pro integrated solutions	CE	
	Near Patient Care	Accu-Chek SmartGuide (Continuous Glucose Monitoring)	Launch of Roche's first generation Continuous Glucose Monitoring (CGM) solution	CE	
	Molecular Lab	cobas 6800/8800 v2.0	Upgraded system with increased flexibility, higher throughput and greater automation to enable broader test menu. Retrofittable with existing cobas 6800/8800 installed base	CE	
	Pathology Lab	Primary Diagnosis Claim on DP600 US	FDA 510k Primary Diagnosis clearance on DP600 scanner as a critical step to advance Digital Pathology	US	
Tests	Core Lab	cobas pro serology solution (blood screening)	FDA approval of our serology Roche Blood Safety Solution (RBSS) for the US donor screening market (largest donor screening market globally)	US	
	Near Patient Care	cobas Liat Respiratory Panel (SARS-CoV-2, Flu A/B & RSV)	Detection and differentiation of four respiratory targets: SARS-CoV-2, Influenza A, Influenza B & respiratory syncytial virus (RSV)	US EUA	
	Molecular Lab	cobas Respiratory flex	Using novel Temperature Assisted Generation of Signal (TAGS®) Multiplex technology & digital reflex approach, enables strategic efficiency with flexible testing for cobas x800 Systems	CE US	
		cobas Malaria (blood screening)	RT qualitative PCR test on the cobas® x800 systems detecting all five plasmodium species that occur in humans. Utilized for malaria screening of blood donors, blood products, organs, and tissues	CE US	✔ US
	Pathology Lab	VENTANA Kappa Lambda Dual ISH mRNA Probe Cocktail	Aid in diagnosis of B-cell lymphomas and plasma cell neoplasms	CE US	
Digital solutions	Diagnostics Insights	navify Analytics family	Supports lab directors/managers to track, review, identify trends/challenges and optimize operations. Has four apps tailored to Core, Pathology, Molecular Labs and Point of Care	Global	

RT=real time

Invitation to Roche Diagnostics Investor Day 2024

Innovating Diagnostics, shaping healthcare, changing lives

cobas i601 mass spectrometry system

Roche Diagnostics Investor Day on May 22

London / hybrid event

14:00 - 16:30 CEST / 13:00 – 15:30 BST
08:00 – 10:30 am EDT / 05:00 – 07:30 am PDT

Highlights:

- Deep-dive into the current product portfolio
- Updates on key development projects and upcoming launches, including mass spectrometry, CGM, NGS

Presenters include:

- **Matt Sause**, CEO Roche Diagnostics
- **Alan Hippe**, Chief Financial and IT Officer
- **Palani Kumaresan**, Head of Roche Diagnostics Solutions (RDS)
- **Benjamin Lilienfeld**, LCL Serum Work Area Systems
- **Jochen Berchtold**, Franchise Lead Insulin Therapy Solutions
- **Ildikó Amann-Zalán**, Head of Research & Development RDS
- **Nico Michel**, LCL Infectious Diseases - Molecular Lab
- **Jill German,** Head of Pathology Lab
- **Olivier Gillieron**, LCL Cardiometabolic and Neurology

CGM=continuous glucose monitoring; NGS=next generation sequencing; LCL=Lifecycle Leader

Roche Group development pipeline

Marketed products development programmes

Roche Pharma global development programmes

Roche Pharma research and early development (pRED)

Genentech research and early development (gRED)

Spark

Pharma sales appendix

Diagnostics sales appendix

Foreign exchange rates information

Changes to the development pipeline

Q1 2024 update

New to phase I

New to phase II

New to phase III

2 AIs:
RG6058 tiragolumab + Tecentriq - NSCLC adj.
RG7716 Vabysmo - myopic choriodial neovascularization (CNV)

New to registration

1 AI (US):
RG3625 TNKase - stroke

Removed from phase I

4 NMEs:
RG6526 camonsertib - solid tumors
RG6185 belvarafenib + Cotellic ± T - solid tumors
RG6286 NME - CRC
RG6163 NME - psychiatric disorders

Removed from phase II

Removed from phase III

1 AI:
RG6168 Enspryng - myasthenia gravis

Approvals

2 AI (US):
RG3648 Xolair - food allergy
RG7853 Alecensa - ALK+ NSCLC adj.

Status as of April 17, 2024

Roche Group development pipeline

Phase I (48 NMEs + 8 AIs)

RG6026	Columvi monotherapy + combos	heme tumors
RG6058	tiragolumab combos	solid tumors
RG6076	englumafusp alfa combos	heme tumors
RG6114	inavolisib	solid tumors
RG6160	cevostamab	r/r multiple myeloma
RG6171	giredestrant monotherapy + combos	solid tumors
RG6194	runimotamab	breast cancer
RG6234	forimtamig monotherapy + combos	multiple myeloma
RG6279	eciskafusp alfa ± T	solid tumors
RG6292	vopikitug combos	solid tumors
RG6323	efbalropoendekin alfa (IL15/IL15Ra-Fc) ± T	heme & solid tumors
RG6330	divarasib monotherapy + combos	solid tumors
RG6333	CD19 x CD28 + Columvi	r/r NHL
RG6344	BRAF inhibitor (3)	solid tumors
RG6411	-	solid tumors
RG6433	migoprotafib (SHP2i) combos	solid tumors
RG6440	anti-latent TGF-β1 (SOF10)	solid tumors
RG6457	WRN covalent inhibitor	solid tumors
RG6468	-	solid tumors
RG6512	FIXa x FX	Hemophilia
RG6524	DLL3 trispecific	solid tumors
RG6537	AR degrader	mCRPC
RG6538[1]	P-BCMA-ALLO1	heme tumors
RG6596[2]	HER2 TKI	HER2+ BC
RG6614	USP1 inhibitor	solid tumors
RG7827	FAP-4-1BBL combos	solid tumors
RG7828	Lunsumio monotherapy + combos	heme tumors
CHU	glypican-3 x CD3	solid tumors
CHU	codrituzumab	HCC
CHU	CD137 switch antibody	solid tumors
CHU	RAS inhibitor	solid tumors
CHU	SPYK04	solid tumors
CHU	anti-CLDN6 trispecific	CLDN6+ solid tumors
CHU	ROSE12	solid tumors
RG6107	PiaSky (crovalimab)	lupus nephritis
RG6287	-	immunology
RG6315	-	fibrosis
RG6382	-	SLE
RG6418*	selnoflast	inflammation
RG6421	TMEM16A potentiator	cystic fibrosis
RG7828	Lunsumio	SLE
CHU	anti-HLA-DQ2.5 x gluten peptides	celiac disease
CHU	RAY121	Immunology
RG6006	zosurabalpin	bacterial infections
RG6436***	LepB inhibitor	complicated urinary tract infection
RG6449	HBsAg MAb	chronic hepatitis B
RG6640[3]	GLP-1/GIP RA (CT-388)	obesity +/- T2D
RG6652[3]	GLP-1 RA (CT-996)	obesity +/- T2D
RG6035	Brainshuttle™ CD20	multiple sclerosis
RG6182	MAGL inhibitor	multiple sclerosis
RG6289	gamma-secretase modulator	Alzheimer's
RG6120	zifibancimig	nAMD
RG6209	-	retinal disease
RG6351	-	retinal disease
RG7921	-	RVO
CHU	REVN24	acute diseases

Phase II (20 NMEs + 10 AIs)

RG6058	tiragolumab + T	NSCLC
	tiragolumab + T + chemo	NSCLC periadjuvant
	tiragolumab + T	1L PD-L1+ mSCCHN
RG6107	PiaSky (crovalimab)	sickle cell disease
RG6139	tobemstomig monotherapy + combos	solid tumors
RG6171	giredestrant	endometrial cancer
RG6180	autogene cevumeran	solid tumors
RG6357	dirloctogene samoparvovec	hemophilia A
RG6341	-	chronic cough
RG6536	vixarelimab	IPF/SSc-ILD
RG6631[4]	anti-TL1A	ulcerative colitis
RG6631[4]	anti-TL1A	Crohn's disease
RG7854/ RG6346/ RG6084**	ruzotolimod/xalnesiran/PDL1 LNA	HBV
RG6359	SPK-3006	Pompe disease
RG6615[5]	zilebesiran	hypertension
RG6641[3]	GLP-1/GIP RA (CT-868)	T1D with BMI ≥ 25
RG6042	tominersen	Huntington's
RG6102	trontinemab	Alzheimer's
RG6237	anti-latent myostatin + Evrysdi	SMA
	anti-latent myostatin	FSHD
RG6356	Elevidys	0 to <4 year old DMD
RG6416	bepranemab	Alzheimer's
RG7816	alogabat	ASD
RG7935	prasinezumab	Parkinson's
RG6179	vamikibart	DME
RG6299[6]	ASO factor B	geographic atrophy
RG6501	OpRegen	geographic atrophy
CHU	anti-IL-8 recycling antibody	endometriosis

Status as of April 17, 2024

RG-No - Roche/Genentech; CHU - Chugai managed; [1]Poseida Therapeutics managed; [2]co-development with Zion Pharma; [3]Carmot Therapeutics managed; [4]Telavant managed (TUSCANY-2 and TAHOE); [5]Alnylam Pharmaceuticals managed; [6]IONIS managed; T=Tecentriq; *also developed in neurology; **combination platform; *** moving forward with alternative LepB inhibitor (previously RG6319); RA=Receptor agonist

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases
Cardiovascular & Metabolism
Neurology
Ophthalmology
Other

Roche Group development pipeline

Phase III (9 NMEs + 40 AIs)

RG3502	Kadcyla + T	HER-2+ eBC high-risk
RG6026	Columvi + chemo	2L+ DLBCL
	Columvi + Polivy + R-CHP	1L DLBCL
	Columvi	r/r MCL
RG6058	tiragolumab + T	1L PD-L1 high NSCLC
	tiragolumab + T + chemo	1L esophageal cancer
	tiragolumab + T	locally advanced esophageal cancer
	tiragolumab + T	stage III unresectable 1L NSCLC
	tiragolumab + T + chemo	1L non-squamous NSCLC
	tiragolumab + T	NSCLC adj
	tiragolumab + T + Avastin	1L HCC
RG6107	PiaSky (crovalimab)	aHUS
RG6114	inavolisib + palbociclib + fulv.	1L HR+ PIK3CA-mut. mBC
	inavolisib + fulvestrant	post CDKi HR+ PIK3CA-mut. BC
	inavolisib + Phesgo	1L HER2+ PIK3CA-mut. mBC
RG6171	giredestrant + palbociclib	1L ET sensitive ER+/HER2- mBC
	giredestrant	ER+ BC adj
	giredestrant + Phesgo	1L ER+/HER2+ BC
	giredestrant + CDK4/6i	1L ET resistant ER+/HER2- BC
RG6330	divarasib	2L NSCLC
RG7446	Tecentriq + platinum chemo	NSCLC periadj
	Tecentriq + BCG	NMIBC, high-risk
	Tecentriq + capecitabine or carbo/gem	1L TNBC
	Tecentriq + Avastin	HCC adj
	Tecentriq	ctDNA+ high-risk MIBC
	Tecentriq + lurbinectedin	1L maintenance SCLC
RG7601	Venclexta + azacitidine	1L MDS
RG7828	Lunsumio + lenalidomide	2L+ FL
	Lunsumio + Polivy	2L+ DLBCL

RG6149	astegolimab	COPD
RG6299	ASO factor B	IgA nephropathy
RG7159	Gazyva	lupus nephritis
	Gazyva	membranous nephropathy
	Gazyva	systemic lupus erythematosus
	Gazyva	childhood onset idiopathic nephrotic syndrome**
RG6152	Xofluza	influenza, pediatric (0-1 year)
	Xofluza	influenza direct transmission
RG1594	Ocrevus higher dose	RMS & PPMS
RG6168	Enspryng	MOG-AD
	Enspryng	autoimmune encephalitis
RG6356	Elevidys	DMD
RG7845	fenebrutinib	RMS
	fenebrutinib	PPMS
RG6168	Enspryng	TED
RG6179	vamikibart	UME
RG6321	Susvimo	DME
	Susvimo	DR
	Susvimo	wAMD, 36-week
RG7716	Vabysmo	CNV

Registration US & EU (1 NME + 6 AIs)

RG6107*	PiaSky (crovalimab)	PNH
RG7446	Tecentriq SC[1]	all approved indications
RG7853	Alecensa[2]	ALK+ NSCLC adj
RG1594	Ocrevus SC	RMS & PPMS
RG3625	TNKase[3]	stroke
RG7716	Vabysmo[2]	BRVO
	Vabysmo[2]	CRVO

T=Tecentriq
*Approved in China Q1 2024
**also known as pediatric nephrotic syndrome (PNS)
[1]Approved in EU, filed in US
[2]Approved in US, filed in EU
[3]Filed in US

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases
Cardiovascular & Metabolism
Neurology
Ophthalmology
Other

Status as of April 17, 2024

Expected regulatory submissions*

New Molecular Entities: Lead and additional indications

- New Molecular Entity (NME)
- Additional Indication (AI)
- Oncology / Hematology
- Immunology
- Infectious Diseases
- Cardiovascular & Metabolism
- Neurology
- Ophthalmology
- Other

*Filing timelines reflect the anticipated filing of a potential indication; projects shown are in phase II and phase III
✓ Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU
T=Tecentriq, RA=Receptor agonist
[1]Telavant managed (TUSCANY-2 and TAHOE)
[2]IONIS managed
[3]Alnylam Pharmaceuticals managed
[4]Carmot Therapeutics managed

2024

RG6114	**Inavolisib + palbociclib + fulvestrant** 1L HR+ PIK3CA-mut. mBC
RG6356	**Elevidys** DMD (EU)
RG6321	**Susvimo** DME (US)
RG6321	**Susvimo** DR (US)

2025

RG6058	**tiragolumab + T** 1L PD-L1 high NSCLC
RG6058	**tiragolumab + T** Stage III unresectable 1L NSCLC
RG6149	**astegolimab** COPD
RG6321	**Susvimo** wAMD (EU)

2026

RG6058	**tiragolumab + T + chemo** 1L esophageal cancer (CN)
RG6058	**tiragolumab + T** locally adv esophageal cancer
RG6107	**PiaSky (crovalimab)** aHUS
RG6171	**giredestrant + palbociclib** 1L ET sensitive ER+/HER2- mBC
RG7845	**fenebrutinib** RMS &PPMS
RG6179	**vamikibart** UME
RG6321	**Susvimo** DME (EU)

2027 and beyond

RG6058	**tiragolumab + T + chemo** 1L non-sq NSCLC
RG6058	**tiragolumab + T** NSCLC adj
RG6058	**tiragolumab + T** 1L PD-L1+ mSCCHN
RG6058	**tiragolumab+T+/-chemo** NSCLC periadjuvant
RG6058	**tiragolumab+T+ Avastin** 1L HCC
RG6107	**PiaSky (crovalimab)** sickle cell disease
RG6114	**Inavolisib + fulvestrant** post CDKi HR+ PIK3CA-mut. BC
RG6114	**inavolisib + Phesgo** 1L HER2+ PIK3CA-mut. mBC
RG6139	**tobemstomig** solid tumors
RG6171	**giredestrant** ER+ BC adj
RG6171	**giredestrant + Phesgo** 1L ER+/HER2+ BC
RG6171	**giredestrant** endometrial cancer
RG6171	**giredestrant + CDK4/6i** 1L ET resistant ER+/HER2- BC
RG6180	**autogene cevumeran** solid tumors
RG6330	**divarasib** 2L NSCLC
RG6299	**ASO factor B** IgA nephropathy
RG6341	**NME** chronic cough
RG6536	**vixarelimab** IPF & SSc-ILD
RG6631[1]	**anti-TL1A** ulcerative colitis
RG6631[1]	**anti-TL1A** Crohn's disease
RG7854/ RG6346/ RG6084	**ruzotolimod/xalnesiran/ PDL1 LNA** HBV
RG6042	**tominersen** Huntington's
RG6102	**trontinemab** Alzheimer's
RG6237	**anti-latent myostatin + Evrysdi** SMA
RG6237	**anti-latent myostatin** FSHD
RG6356	**Elevidys** 0 to <4 year old DMD
RG6416	**bepranemab** Alzheimer's
RG7816	**alogabat** ASD
RG7935	**prasinezumab** Parkinson's
RG6179	**vamikibart** DME
RG6299[2]	**ASO factor B** geographic atrophy
RG6321	**Susvimo** wAMD, 36-week refill
RG6501	**OpRegen** geographic atrophy
RG6615[3]	**zilebesiran** hypertension
RG6641[4]	**GLP-1/GIP RA (CT-868)** T1D with BMI ≥ 25

Status as of April 17, 2024

Expected regulatory submissions*

Marketed products: Additional indications

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases

Cardiovascular & Metabolism
Neurology
Ophthalmology
Other

✓ Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU
*Filing timelines reflect the anticipated filing of a potential indication; projects shown are in phase II and phase III
**also known as pediatric nephrotic syndrome (PNS)

2024		2025		2026		2027 and beyond	
RG6026	**Columvi + chemo** 2L DLBCL	RG7159	**Gazyva** lupus nephritis	RG7828	**Lunsumio + lenalidomide** 2L FL+	RG7159	**Gazyva** membranous nephropathy	RG3502	**Kadcyla + Tecentriq** HER-2+ eBC high-risk
RG7446	**Tecentriq + Avastin** HCC adj	RG3625	**TNKase** stroke ✓	RG7828	**Lunsumio + Polivy** 2L+ DLBCL (US)	RG7159	**Gazyva** systemic lupus erythematosus	RG6026	**Columvi + Polivy + R-CHP** 1L DLBCL
RG7446	**Tecentriq + capecitabine or carbo/gem** TNBC	RG6152	**Xofluza** direct transmission	RG7446	**Tecentriq+ lurbinectedin** 1l maintenance SCLC			RG6026	**Columvi** r/r MCL
		RG6152	**Xofluza** influenza, pediatric (0-1 year)	RG7446	**Tecentriq** ctDNA+ high-risk MIBC			RG7446	**Tecentriq + BCG** High-risk NMIBC
				RG7446	**Tecentriq** NSCLC periadj			RG7159	**Gazyva** childhood onset idiopathic nephrotic syndrome**
				RG7601	**Venclexta + azacitidine** 1L MDS			RG6168	**Enspryng** MOG-AD
				RG1594	**Ocrevus higher dose** RMS & PPMS			RG7716	**Vabysmo** CNV
				RG6168	**Enspryng** TED				

Status as of April 17, 2024

Major pending approvals 2024

US		EU		China		Japan-Chugai	
RG7446	**Tecentriq SC** all approved indications Filed Nov 2022	RG6107	**PiaSky (crovalimab)** PNH Filed June 2023	RG7716	**Vabysmo** BRVO/CRVO Filed March 2023	RG7853	**Alecensa** ALK+ NSCLC adj Filed Dec 2023
RG6107	**PiaSky (crovalimab)** PNH Filed June 2023	RG7716	**Vabysmo** BRVO/CRVO Filed Aug 2023	RG1594	**Ocrevus** RMS & PPMS Filed June 2023	RG7916	**Evrysdi** SMA presymptomatic pediatric <2mo Filed Feb 2024
RG1594	**Ocrevus SC** RMS & PPMS Filed Nov 2023	RG1594	**Ocrevus SC** RMS & PPMS Filed Aug 2023	RG7853	**Alecensa** ALK+ NSCLC adj Filed Nov 2023	RG7446	**Tecentriq** Alveolar Soft Part Sarcoma Filed March 2024
		RG7853	**Alecensa** ALK+ NSCLC adj Filed Nov 2023	RG7828	**Lunsumio** 3L+ FL Filed Dec 2023	RG7828	**Lunsumio** 3L+ FL Filed March 2024
						RG99	**CellCept** SSc-ILD Filed March 2024

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases

Cardiovascular & Metabolism
Neurology
Ophthalmology
Other

Status as of April 17, 2024

Major granted approvals 2024

US		EU		China		Japan-Chugai	
RG3648	**Xolair** Food allergy Feb 2024	RG7446	**Tecentriq SC** all approved indications Jan 2024	RG6107	**PiaSky (crovalimab)** PNH Feb 2024*	RG6107	**PiaSky (crovalimab)** PNH March 2024
RG7853	**Alecensa** ALK+ NSCLC adj April 2024					RG7716	**Vabysmo** BRVO/CRVO March 2024

*First worldwide appoval

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases

Cardiovascular & Metabolism
Neurology
Ophthalmology
Other

Status as of April 17, 2024

Doing now what patients need next